LOTENSIN

Compare LOTENSIN  to:
Compare
Compare

Generic Name for LOTENSIN

Benazepril (as HCl) 5mg, 10mg, 20mg, 40mg; tabs.

Legal Classification:

Rx

Pharmacological Class for LOTENSIN

ACE inhibitor.

Manufacturer of LOTENSIN

Novartis Pharmaceuticals Corp

Indications for LOTENSIN

Hypertension.

Adult dose for LOTENSIN

If not on diuretic: initially 10mg daily. Usual maintenance: 20–40mg daily in 1 or 2 divided doses; usual max 80mg/day. If on diuretic: discontinue diuretic, if possible, 2–3 days before starting; resume diuretic if pressure not controlled with benazepril alone. If diuretic cannot be discontinued: initially 5mg daily. Creatinine clearance <30mL/min/1.73m2: initially 5mg daily; max 40mg/day.

Children's dosing for LOTENSIN

Not recommended.

Contraindications for LOTENSIN

History of ACEI-associated or other angioedema. Pregnancy (Cat.D in 2nd and 3rd trimesters).

Precautions for LOTENSIN

Salt/volume depletion. Renal or hepatic impairment. Monitor WBCs in renal or collagen vascular disease. CHF. Dialysis (esp. high-flux membrane). Renal artery stenosis. Monitor for hyperkalemia in diabetics. Surgery. Discontinue if angioedema or laryngeal edema occurs. Pregnancy (Cat.C in 1st trimester). Nursing mothers.

Interactions for LOTENSIN

Potassium or potassium-sparing diuretics may cause hyperkalemia. May increase lithium levels. Potentiated by diuretics.

Adverse Reactions for LOTENSIN

Headache, dizziness, fatigue, GI upset, cough, angioedema, orthostatic hypotension, hyperkalemia.

How is LOTENSIN supplied?

Tabs—100

Related Disease:

Hypertension

Related Resources

The Medicines Company expands Cleviprex recall

March 18, 2010

The FDA and The Medicines Company have notified healthcare professionals of an additional recall of 4 lots of Cleviprex (clevidipine butyrate injectable emulsion).

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.